Literature DB >> 7767506

Smooth muscle cell de-differentiation is a fundamental change preceding wound healing after percutaneous transluminal coronary angioplasty in humans.

M Ueda1, A E Becker, T Naruko, A Kojima.   

Abstract

BACKGROUND: Wound healing at the site of medial injury after percutaneous transluminal coronary angioplasty (PTCA) is dominated by smooth muscle cells. This reaction may also cause restenosis. Division and migration of smooth muscle cells relate closely to their cytoskeletal features, as shown experimentally, but in humans little information is available regarding smooth muscle cell activity in post-angioplasty coronary arteries.
MATERIALS AND METHODS: This study is based on eight dilated coronary arteries obtained at autopsy from six patients who died within 4 months of an initially successful PTCA. In each patient, a single PTCA had been performed and the target site was identified, sectioned serially, and studied with conventional and immunohistochemical techniques.
RESULTS: All target sites showed laceration extending into the media. Two days after PTCA the site of injury was covered by a fibrin-platelet thrombus. The smooth muscle cells of the pre-existent media, immediately adjacent to the site of injury, showed loss of staining for both muscle actin and smooth muscle cell actin, using the antibodies HHF-35 (an anti-muscle actin marker) and CGA-7 (an anti-smooth muscle cell actin marker), respectively. Five days after PTCA, this area had expanded; a distinct influx of macrophages was apparent. From 12 days onwards, the staining density with HHF-35 in the pre-existent media increased and was almost restored to normal at 20 days, but staining with CGA-7 was retarded until approximately 4 months after PTCA. In the repair tissue, spindle-shaped cells were first seen 5 days after PTCA. These cells stained positive with vimentin but did not stain with either actin marker. Macrophages were present at this stage. At 12 days after PTCA, some spindle-shaped cells stained positive with HHF-35, but all were negative with CGA-7. At 16 days, the staining density with HHF-35 had increased, but CGA-7 was still negative. At 20 days, the maximal staining density with HHF-35 was obtained. The vast majority of spindle-shaped cells also stained positive with CGA-7 4 months after PTCA. Endothelial cells on the luminal surface were first identified 4 months after PTCA.
CONCLUSION: The observations provide support that cytoskeletal changes observed experimentally also play a role in human coronary arteries after PTCA. De-differentiation of smooth muscle cells of the pre-existent media, preceding a noticeable cellular response, appears to be a fundamental process.

Entities:  

Mesh:

Year:  1995        PMID: 7767506     DOI: 10.1097/00019501-199501000-00011

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  11 in total

1.  Phenotypic change and accumulation of smooth muscle cells in strictures in Crohn's disease: relevance to local angiotensin II system.

Authors:  Takehisa Suekane; Yoshihiro Ikura; Kenji Watanabe; Junko Arimoto; Yoko Iwasa; Yoshimi Sugama; Soichiro Kayo; Kenichi Sugioka; Takahiko Naruko; Kiyoshi Maeda; Kosei Hirakawa; Tetsuo Arakawa; Makiko Ueda
Journal:  J Gastroenterol       Date:  2010-04-02       Impact factor: 7.527

2.  Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study.

Authors:  S Tanizawa; M Ueda; C M van der Loos; A C van der Wal; A E Becker
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 3.  Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.

Authors:  Larissa Lipskaia; Lahouaria Hadri; Jose J Lopez; Roger J Hajjar; Regis Bobe
Journal:  Curr Vasc Pharmacol       Date:  2013-07       Impact factor: 2.719

4.  Role of endothelial cell denudation and smooth muscle cell dedifferentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications.

Authors:  Y Sasaki; S Suehiro; A E Becker; H Kinoshita; M Ueda
Journal:  Heart       Date:  2000-01       Impact factor: 5.994

5.  In situ detection of platelet-derived growth factor-A and -B chain mRNA in human coronary arteries after percutaneous transluminal coronary angioplasty.

Authors:  M Ueda; A E Becker; N Kasayuki; A Kojima; Y Morita; S Tanaka
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

6.  Suppressed smooth muscle proliferation and inflammatory cell invasion after arterial injury in elafin-overexpressing mice.

Authors:  S H Zaidi; X M You; S Ciura; S O'Blenes; M Husain; M Rabinovitch
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

7.  SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery.

Authors:  L Lipskaia; L Hadri; P Le Prince; B Esposito; F Atassi; L Liang; M Glorian; I Limon; A-M Lompre; S Lehoux; R J Hajjar
Journal:  Gene Ther       Date:  2012-07-05       Impact factor: 5.250

8.  Cerebral artery restenosis following transluminal balloon angioplasty for vasospasm after subarachnoid hemorrhage.

Authors:  Katsuya Umeoka; Shushi Kominami; Takayuki Mizunari; Yasuo Murai; Shiro Kobayashi; Akira Teramoto
Journal:  Surg Neurol Int       Date:  2011-04-19

9.  Role of Notch1 in the arterial specification and angiogenic potential of mouse embryonic stem cell-derived endothelial cells.

Authors:  Jae Kyung Park; Tae Wook Lee; Eun Kyoung Do; Hye Ji Moon; Jae Ho Kim
Journal:  Stem Cell Res Ther       Date:  2018-07-18       Impact factor: 6.832

10.  Efficient transduction of vascular smooth muscle cells with a translational AAV2.5 vector: a new perspective for in-stent restenosis gene therapy.

Authors:  A-M Lompré; L Hadri; E Merlet; Z Keuylian; N Mougenot; I Karakikes; J Chen; F Atassi; A Marchand; R Blaise; I Limon; S W J McPhee; R J Samulski; R J Hajjar; L Lipskaia
Journal:  Gene Ther       Date:  2013-03-28       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.